Chemoprevention Trial of Contralateral Breast Cancer with Fenretinide. Rationale,Design,Methodology,Organization,Data Management,Statistics and Accrual
Restricted accessResearch articleFirst published online November, 1997
Chemoprevention Trial of Contralateral Breast Cancer with Fenretinide. Rationale,Design,Methodology,Organization,Data Management,Statistics and Accrual
The Fenretinide (4-HPR) Breast Cancer Study is a randomized multicenter clinical trial originally designed and conducted by the investigators of the Istituto Nazionale Tumori of Milan. The study is sponsored by the National Cancer Institute of Bethesda and by the Italian National Research Council. The trial was designed to evaluate the effectiveness of the synthetic retinoid 4-HPR, at a dose of 200 mg per os every day for 5 years, in reducing the incidence of contralateral breast cancer in a population of patients previously operated on for breast cancer. Between 1987 and 1993, the Istituto Nazionale Tumori of Milan and 9 other collaborating Centers enrolled 2,972 women between the ages of 30 and 70 years who had been previously operated on for T1-T2 N- M0 breast cancer. This paper describes the rationale, design, methodology, organization, data management, statistics and accrual of the participating population.
BroetP., de-la-RochefordiereA., SchollS.M., FourquetA., MosseriV., DurandJ.C., PouillartP., AsselainB.: Contralateral breast cancer: annual incidence and risk parameters.J. Clin. Oncol.,13: 1578–1583, 1995.
2.
CostaA., MaloneW., PerloffM., BuranelliF., CampaT., DossenaG., MagniA., PizzichettaM, AndreoliC., Del VecchioM., FormelliF., BarbieriA.: Tolerability of the synthetic retinoid fenretinide (HPR).Eur. J. Cancer Clin. Oncol.,25: 805–808, 1989.
3.
CoxD.R.: Regression models and life tables.J. Royal Stat. Soc.,34: 187–220, 1972.
4.
DevesaS.S., BlotW.J., StoneB.J., MillerB.A., TaroneR.E., FraumeniJ.F.Jr.: Recent cancer trends in the United States.J. Natl. Cancer Inst.,87: 175–182, 1995.
5.
DooseD.R., MinnF.L., StellarS., NayakR.K.: Effects of meals and meal composition on the bioavailability of fenretinide.J. Clin. Pharmacol.,32: 1089–1095, 1992.
6.
DowlatshahiK., MehtaR.G., ThomasC.F., DingerN.M., MoonR.C.: Therapeutic effect of N-(4-hydroxyphenyl)retinamide on N-methyl-N-nitrosourea-induced rat mammary cancer.Cancer Lett.,47: 187–192, 1989.
7.
FanjulA.N., DeliaD., PierottiD., RideoutD., QiuJ., PfahlM.: 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors.J. Biol. Chem.,271: 22441–22446, 1996.
8.
FormelliF., BaruaA.B., OlsonJ.A.: Bioactivities of N-(4-hydroxyphenyl)retinamide and retinol β-glucuronide.FASEB J.,10: 1014–1024, 1996.
FormelliF., CarsanaR., CostaA., BuranelliF., CampaT., DossenaG., MagniA., PizzichettaM.: Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.Cancer Res.,48: 6149–6152, 1989.
11.
FormelliF., ClericiM., CampaT., Di MauroM.G., MagniA., MascottiG., MogliaD., De PaloG., CostaA., VeronesiU.: Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations.J. Clin. Oncol.,11: 2036–2042, 1993.
12.
HankleyB.F., CurtisR.E., NaughtonM.D., BoiceJ.D., FlanneryJ.T.: A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the efficacy of the radiation therapy.J. Natl. Cancer Inst.,70: 797–804, 1983.
13.
HennekensC.H., BuringJ.E., MansonJ.E., StampferM., RosnerB., CookN.R., BelangerC., LaMotteF., GazianoJ.M., RidkerP.M., WillettW., PetoR.: Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease.N. Engl. J. Med.,334: 1145–1149, 1996.
14.
Kaiser-KupferM.I., PeckG.L., CarusoR.C., JaffeM.J., Di GiovannaJ.J., GrossE.G.: Abnormal retinal function associated with fenretinide, a synthetic retinoid.Arch. Ophthalmol.,104: 69–70, 1986.
15.
KenelM.F., KrayerJ.H., MerzE.A.: Teratogenicity of N-(4-hydroxyphenyl)-all-trans-retinamide in rats and rabbits.Teratog. Carcinog. Mutag.,8: 1–11, 1988.
16.
KingstoneT.P., LoweN.J., WinstonJ., HeckenlivelyJ.: Visual and cutaneous toxicity which occurs during N-(4-hydroxyphenyl)retinamide therapy for psoriasis.Clin. Exper. Dermatol.,11: 624–627, 1986.
17.
KurtzJ.M., AlmaricR., BrandoneH., AymeY., SpitalierJ.M.: Contralateral breast cancer and other second malignancies in patients treated by breast-conserving therapy with radiation.Int. J. Rad. Oncol. Biol. Phys.,15: 277–284, 1988.
18.
LotanR.: Retinoids and apoptosis: implications for cancer chemoprevention and therapy.J. Natl. Cancer Inst.,87: 1655–1657, 1995.
19.
MarubiniE., MarianiL.: Statistical aspects of chemoprevention trials. In: Progress and Perspectives in Chemoprevention of Cancer, De PaloG., SpornM., VeronesiU. (Eds.), Serono Symposia Publications, vol. 79, pp, 107–116, Raven Press, New York, 1992.
20.
McCormickD.L., MethaR.G., ThompsonC.A., DingerN., CaldwellJ.A., MoonR.C.: Enhanced inhibition of mammary carcinogenesis by combined treatment with N-(4-hydroxyphenyl)retinamide and ovariectomy.Cancer Res.,42: 508–512, 1982.
21.
McCormickD.L., MoonR.C.: Retinoid-tamoxifen interaction in mammary cancer chemoprevention.Carcinogenesis,7: 193–196, 1986.
22.
MehtaR.G., MoonR.C., HawthorneM., FormelliF., CostaA.: Distribution of fenretinide in the mammary gland of breast cancer patients.Eur. J. Cancer,27: 139–141, 1991.
23.
MoonR.C., ThompsonH.J., BecciJ.P., GrubbsC.J., GanderR.J., NewtonD.L., SmithJ.M., PhillipsS.L., HendersonW.R., MullenL.T., BrownC.C., SpornM.B.: N-(4-hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat.Cancer Res.,39: 1339–1346, 1979.
24.
NayfieldS.G., KarpJ.E., FordL.G., DorrA., KramerB.S.: Potential role of tamoxifen in prevention of breast cancer.J. Natl. Cancer Inst.,83: 1450–1459, 1991.
25.
OmennG.S., GoodmanG.E., ThornquistM.D., BalmesJ., CullenM.R., GlassA., KeoghJ.P., MeyskensF.L., ValanisB., WilliamsJ.H., BarnhartS., HammarS.: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease.N. Engl. J. Med.,334: 1150–1155, 1996.
26.
PaulsonJ.D., OldhamJ.W., PrestonR.F., NewmanD.: Lack of genotoxicity of the cancer chemopreventive agent N-(4-hydroxyphenyl)retinamide.Fundam. Appl. Toxicol.,5: 144–150, 1985.
27.
RadcliffeJ.D., MoonR.C.: Effect of N-(4-hydroxyphenyl)retinamide on food intake, growth and mammary gland development in rats.Proc. Soc. Exp. Biol. Med.,174: 270–275, 1983.
28.
RatkoT.A., DetrisacC.J., DingerN.M., ThomasC.F., KelloffG.J., MoonR.C.: Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats.Cancer Res.,49: 4472–4476, 1989.
29.
SpornM.B., NewtonD.L.: Chemoprevention of cancer with retinoids.Fed. Proc.,38: 2528–2534, 1979.
30.
The Alpha Tocopherol, Beta Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.N. Engl. J. Med.,330: 1029–1035, 1994.
31.
UICC: TNM classification of malignant tumours.Fourth edn., Springer-Verlag, Berlin, Heidelberg, New York, 1987.
32.
WuM., FisherM., DeMetsD.: Sample sizes for long-term medical trial with time dependent drop-out and event rates.Controlled Clin. Trials,1: 109–121, 1980.
33.
ZuckerD.M., LakatosE.: Weighted log rank type statistics for comparing survival curves when there is a lag time in the effectiveness of treatment.Biometrika,77: 853–864, 1990.
